Intra-Cellular Therapies, Inc. Appoints Professor Sir Michael Rawlins to its Board of Directors
5/14/2013 7:09:39 AM
More...
|
Intra-Cellular Therapies, Inc. Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
2/19/2013 10:20:25 AM
More...
|
Intra-Cellular Therapies, Inc. and Takeda Pharmaceutical Co. Ltd. (TKDG.DE) Enter into Worldwide Collaboration to Develop and Commercialize Compounds for Schizophrenia in Deal Worth $750 Million Potentially
3/3/2011 8:55:40 AM
More...
|
Intra-Cellular Therapies, Inc. Announces Positive Results with ITI-002 in Pre-Clinical Models of Parkinson's Disease
10/1/2010 8:25:29 AM
More...
|
Intra-Cellular Therapies, Inc. Announces the Successful Completion of a Phase Ib/II Study of ITI-007 in Patients with Schizophrenia
7/29/2010 10:47:18 AM
More...
|
Intra-Cellular Therapies, Inc. Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
3/10/2009 9:13:48 AM
More...
|
Intra-Cellular Therapies, Inc. Announces Successful Outcome of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
1/13/2009 8:53:51 AM
More...
|
Intra-Cellular Therapies, Inc. Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722
4/9/2008 7:10:04 AM
More...
|
Intra-Cellular Therapies, Inc. Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs
2/15/2008 7:08:34 AM
More...
|
Intra-Cellular Therapies, Inc. Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
12/20/2007 8:23:59 AM
More...
|
|